Teva Pharmaceutical Industries (STU:TEV) Cyclically Adjusted Book per Share: €13.78 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:TEV Teva Pharmaceutical Industries Ltd STU:TEV
50 GF Score
Price €31.60
GF Value €17.91
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Teva Pharmaceutical Industries Cyclically Adjusted Book per Share?

Teva Pharmaceutical Industries STU:TEV +0.96% 50 Cyclically Adjusted Book per Share is €13.78 as of Jun. 2026. GuruFocus rates STU:TEV with a GF Score™ of 50/100 and a GF Value™ of €17.91 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Teva Pharmaceutical Industries's adjusted book value per share for the three months ended in Jun. 2026 was €5.824. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €13.78 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Teva Pharmaceutical Industries's average Cyclically Adjusted Book Growth Rate was -15.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -11.80% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -8.50% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -4.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Teva Pharmaceutical Industries was 29.10% per year. The lowest was -11.80% per year. And the median was 19.70% per year.

As of today (2026-09-18), Teva Pharmaceutical Industries's current stock price is €31.60. Teva Pharmaceutical Industries's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €13.78. Teva Pharmaceutical Industries's Cyclically Adjusted PB Ratio of today is 2.29.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Teva Pharmaceutical Industries was 2.60. The lowest was 0.27. And the median was 0.69.


Teva Pharmaceutical Industries  (STU:TEV) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Teva Pharmaceutical Industries's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=31.60/13.784
=2.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Teva Pharmaceutical Industries was 2.60. The lowest was 0.27. And the median was 0.69.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Teva Pharmaceutical Industries Cyclically Adjusted Book per Share Related Terms


Teva Pharmaceutical Industries Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Teva Pharmaceutical Industries's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teva Pharmaceutical Industries Cyclically Adjusted Book per Share Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.95 19.35 18.10 16.07 13.38

Teva Pharmaceutical Industries Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.29 15.72 14.91 14.44 13.78

STU:TEV vs ZTS, UTHR, VTRS: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teva Pharmaceutical Industries Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's Cyclically Adjusted PB Ratio falls into.


STU:TEV
50GF Score
Teva Pharmaceutical Industries Ltd STU:TEV
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Teva Pharmaceutical Industries Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Teva Pharmaceutical Industries's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=5.824/333.9520*333.9520
=5.824

Current CPI (Jun. 2026) = 333.9520.

Teva Pharmaceutical Industries Quarterly Data

Book Value per Share CPI Adj_Book
201609 29.288 241.428 40.512
201612 29.305 241.432 40.535
201703 29.563 243.801 40.495
201706 22.427 244.955 30.575
201709 22.209 246.819 30.049
201712 12.376 246.524 16.765
201803 13.104 249.554 17.536
201806 13.132 251.989 17.403
201809 12.935 252.439 17.112
201812 12.675 251.233 16.848
201903 12.915 254.202 16.967
201906 12.264 256.143 15.989
201909 12.535 256.759 16.304
201912 12.289 256.974 15.970
202003 12.136 258.115 15.702
202006 12.045 257.797 15.603
202009 8.242 260.280 10.575
202012 8.248 260.474 10.575
202103 8.471 264.877 10.680
202106 8.648 271.696 10.630
202109 8.958 274.310 10.906
202112 8.961 278.802 10.734
202203 8.305 287.504 9.647
202206 8.466 296.311 9.541
202209 8.748 296.808 9.843
202212 7.251 296.797 8.159
202303 7.074 301.836 7.827
202306 6.304 305.109 6.900
202309 6.329 307.789 6.867
202312 6.562 306.746 7.144
202403 6.166 312.332 6.593
202406 5.405 314.175 5.745
202409 5.044 315.301 5.342
202412 4.875 315.605 5.158
202503 5.060 319.799 5.284
202506 5.076 322.561 5.255
202509 5.382 324.800 5.534
202512 5.860 324.054 6.039
202603 6.138 330.213 6.208
202606 5.824 333.952 5.824

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €13.78 mean?
Teva Pharmaceutical Industries (STU:TEV) has a Cyclically Adjusted Book per Share of €13.78 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Teva Pharmaceutical Industries and its competitors.
Is Teva Pharmaceutical Industries' Cyclically Adjusted Book per Share too high?
Teva Pharmaceutical Industries' current Cyclically Adjusted Book per Share is €13.78. Overall, Teva Pharmaceutical Industries has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' Cyclically Adjusted Book per Share compare to ZTS and UTHR?
Teva Pharmaceutical Industries' Cyclically Adjusted Book per Share of €13.78 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Teva Pharmaceutical Industries and its competitors. Teva Pharmaceutical Industries's current Cyclically Adjusted Book per Share is €13.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (STU:TEV) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.91, compared to a current price of €31.60 — trading 76.4% above its estimated fair value. The current Cyclically Adjusted Book per Share is €13.78. Teva Pharmaceutical Industries' overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Teva Pharmaceutical Industries (STU:TEV), the current Cyclically Adjusted Book per Share is €13.78 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Teva Pharmaceutical Industries (STU:TEV) Overvalued in 2026?

Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued. The current stock price of €31.60 is trading 76.4% above its estimated GF Value™ of €17.91. GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.

Key valuation signals for STU:TEV:

  • Cyclically Adjusted Book per Share: €13.78
  • GF Value™: €17.91 vs. price of €31.60 (76.4% above fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the STU:TEV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Teva Pharmaceutical Industries Business Description

Address 124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
50GF Score

Get the complete analysis for STU:TEV

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€31.60
Price
€17.91
GF Value